摘要
目的确定《P2Y12受体拮抗剂用于急性冠状动脉综合征或经皮冠状动脉介入治疗患者精准治疗快速建议指南》(简称指南)纳入的临床问题和结局指标。方法通过专家咨询、文献检索起草拟纳入临床问题与结局指标初稿,并征询一线医师和药师意见。最终,由指导委员会确定16个临床问题和19个结局指标在专家会上采取德尔菲法调查。通过积极系数、变异系数进行质量控制。结果专家在会议上补充2个临床问题和3个结局指标。最终,共有13个临床问题必须形成推荐意见或说明,5个临床问题需根据证据质量与专家共识决定是否形成推荐意见,形成15个关键结局与7个重要结局。研究中专家积极程度高,积极系数为100%,变异系数经第2轮匿名反馈后有所降低,专家的意见趋于一致。结论通过3轮德尔菲法调查确定纳入的临床问题与结局指标,为指南的后续制定奠定了良好的基础。
Objective The purpose of this study was to determine the clinical problems and outcomes included in the Rapid Advice Guideline for Precision Therapy of P2 Y12 Receptor Antagonists in Patients with Acute Coronary Syndrome or Percutaneous Coronary Intervention. Methods The first draft including clinical problems and outcomes was drawn by the secretariat,combining the expert interviews and literature retrieval,and consultation with front-line clinicians and pharmacists. Finally,16 clinical problems and 19 outcomes were drafted by the steering committee for Delphi investigation at expert meeting.Active coefficient and coefficient of variation were calculated for quality control. Results 2 clinical problems and 3 outcomes were added by experts at the meeting. Finally,recommendation of 13 clinical problems must be developed,while 5 clinical problems depended on the quality of evidence and the consensus of experts. 15 outcomes were ranked as"critical outcome"and 7 as"important outcome". The active coefficient was 100%. In the third round,the coefficient of variation decreased and the experts came to consensus because of the second round investigation. Conclusion Through three rounds of Delphi investigation,the clinical problems and outcomes were finally produced in order to guide the development of the guideline in the near future.
作者
方振威
石秀锦
周鹏翔
周洋
魏娟娟
董淑杰
丁征
赵紫楠
徐晓宇
张翼
林佰弟
翟所迪
林阳
FANG Zhen-wei;SHI Xiu-jin;ZHOU Peng-xiang;ZHOU Yang;WEI Juan-juan;DONG Shu-jie;DING Zheng;ZHAO Zi-nan;XU Xiao-yu;ZHANG Yi;LIN Bai-di;Suo-di ZHAI;LIN Yang(Department of Pharmacy,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China;Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China;Department of Pharmacy,Fuwai Hospital,Chinese Academy of Medical Sciences,Beijing 100037,China;Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处
《临床药物治疗杂志》
2021年第7期37-42,共6页
Clinical Medication Journal
基金
北京市医院管理中心临床医学发展专项“扬帆”计划科研基金(ZYLX201805)。
